SOX4 and acute myeloid leukemia: Furthermore, with a median follow-up period of 46.7 months (range: 0.3–70.9 months), SOX4 expression was associated with overall survival and disease-free survival in all patients with de novo AML (P=0.008 and P=0.013, respectively, Figure 1c), patients with non-M3 subtypes (P<0.001 and P=0.001, respectively, Figure 1d), patients with intermediate-risk cytogenetics (P=0.001 and P=0.005 respectively, Figure 1e) or even in those with normal karyotype profile (P=0.022 and P=0.111, Figure 1f).